Abstract：
In 2016, the first worldwide n3 PUFA status map was published using the Omega-3 Index (O3I) as standard biomarker. The O3I is defined as the percentage of EPA + DHA in red blood cell (RBC) membrane FAs. The purpose of the present study was to update the 2016 map with new data. In order to be included, studies had to report O3I and/or blood EPA + DHA levels in metrics convertible into an estimated O3I, in samples drawn after 1999. To convert the non-RBC-based EPA + DHA metrics into RBC we used newly developed equations. Baseline data from clinical trials and observational studies were acceptable. A literature search identified 328 studies meeting inclusion criteria encompassing 342,864 subjects from 48 countries/regions. Weighted mean country O3I levels were categorized into very low ≤4%, low >4-6%, moderate >6-8%, and desirable >8%. We found that the O3I in most countries was low to very low. Notable differences between the current and 2016 map were 1) USA, Canada, Italy, Turkey, UK, Ireland and Greece (moving from the very low to low category); 2) France, Spain and New Zealand (low to moderate); and 3) Finland and Iceland (moderate to desirable). Countries such as Iran, Egypt, and India exhibited particularly poor O3I levels.
摘要：
2016年，使用Omega-3指数（O3I）作为标准生物标志物发布了全球第一张n3PUFA状态图。O3I定义为红细胞(RBC)膜FA中EPA+DHA的百分比。本研究的目的是用新数据更新2016年的地图。为了被包括在内,研究必须报告O3I和/或血液EPA+DHA水平的指标可转换为估计的O3I，在1999年后抽取的样本中。为了将基于非RBC的EPA+DHA度量转换成RBC,我们使用新开发的方程。临床试验和观察性研究的基线数据是可以接受的。文献检索确定了328项符合纳入标准的研究，包括来自48个国家/地区的342,864名受试者。加权平均国家O3I水平被归类为非常低≤4%，低>4-6%，中度>6-8%，理想>8%。我们发现大多数国家的O3I低至非常低。当前地图和2016年地图之间的显著差异是1）美国，加拿大,意大利,土耳其,英国,爱尔兰和希腊（从非常低的类别转向低类别）；2）法国，西班牙和新西兰（低到中等）；3）芬兰和冰岛（中等到理想）。伊朗等国家,埃及,印度表现出特别差的O3I水平。
